Shenyang NovPharm Technology Co., Ltd., established in 2007, is a comprehensive pharmaceutical company specialized in the research, development, manufacturing and marketing of a broad range of APIs and high-added-value intermediates. The company owned independent R&D centers and production base. It has independently developed Febuxostat and its intermediates, Dronedarone intermediates, Agomelatine intermediates, Perindopril intermediates, Aliskiren intermediate, etc., and brought them to the market successfully.
With strong research capabilities and spirit of innovation, the company has committed long-term cooperation with many famous domestic universities and research institutions, and established state-of-the-art R&D centers. Every year, NovPharm develops new market oriented high-technology products at the forefront of advanced technology.
Insisting on the management policy of “Product Quality is the Basis for the Survival and Development of the Company”, NovPharm forms an effective process control system and standard quality management system to ensure that our products and services are in accordance with the ever changing international standard. We will wholeheartedly provide high-quality products with competitive price and highly efficient services with science and technology innovation to clients across the globe.